TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03505476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Entac Medical device application
Description: Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
Study: NCT02703779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
Study: NCT03505476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Daily Assessment
Description: The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
Study: NCT02703779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Study: NCT03505476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Discharge Assessment
Description: The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
Study: NCT02779218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: Patient with Paired Associative Stimulation only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: Patient with Paired Associative Stimulation only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation
Description: Patient with Paired Associative Stimulation only

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with Paired Associative Stimulation + Motor Imagery exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with Paired Associative Stimulation + Motor Imagery exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with Paired Associative Stimulation + Motor Imagery exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with placebo Paired Associative Stimulation + Motor Imagery exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with placebo Paired Associative Stimulation + Motor Imagery exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo Paired Associative Stimulation + Motor Imagery exercises
Description: Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
Study: NCT00002912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valspodar
Study: NCT02703779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mozobil
Description: Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
Study: NCT02390973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Study: NCT02317575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT02390973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliopancreatic Diversion with Duodenal Switch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Study: NCT03660007

Intervention type: PROCEDURE
Intervention: Fresh or frozen embryo transfer IVF

Intervention type: PROCEDURE
Intervention: Fresh or frozen embryo transfer IVF
Study: NCT04425642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose/Amino acids
Description: If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose and amino acids solutions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose/Amino acids/Lipids
Description: If indications for parenteral nutrition appear, it's dose will be calculated according patient's age and weight and will consist of glucose, amino acids and lipid emulsions. To prevent potential complications of parenteral nutrition, the target dose will be reached by the third day of therapy. It will discontinued, when the patient oral food intake will be more than 60% for three consecutive days.
Study: NCT02192463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 20%) Medium Release
Study: NCT02579291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath
Description: Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
Study: NCT00465166

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
Study: NCT04327934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist up to 16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist up to 16 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist + MethylTESTOSTERone 5 MG
Description: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist + MethylTESTOSTERone 5 MG
Description: GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.
Study: NCT01430130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: embrace device
Description: Adhesive bandage/dressing intended to minimize scar formation.
Study: NCT03528330

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation with dental implant with internal hexagon connection
Description: All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation with dental implant with conical connection
Description: All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W\&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery
Study: NCT00501449

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
Study: NCT02114502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAHA
Description: 1,000 mg by mouth on Days -8 to -3.
Study: NCT01223079

Intervention type: DRUG
Group type: OTHER
Intervention: r-hFSH
Description: r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response

Intervention type: DRUG
Group type: OTHER
Intervention: r-hFSH and r-hLH
Description: Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
Study: NCT03459417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine+LA
Description: Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine+LA+ Mg sulp. 50
Description: Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine+LA+ Mg sulp. 100
Description: Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
Study: NCT02114502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on Days -3 and -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (SCT)
Description: Stem cell transplant on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg by vein twice a day from Day -9 PM to Day -2 PM.
Study: NCT02854189

Intervention type: DEVICE
Group type: OTHER
Intervention: Oxford unicompartmental knee arthroplasty
Description: The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.

Intervention type: DEVICE
Group type: OTHER
Intervention: Oxford unicompartmental knee arthroplasty
Description: The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
Study: NCT04611997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine Green
Description: Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
Study: NCT02235415

Intervention type: DRUG
Intervention: Motens® (lacidipine)
Study: NCT03613194

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sampling
Description: After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.
Study: NCT03416153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
Study: NCT00003863

Intervention type: GENETIC
Intervention: comparative genomic hybridization

Intervention type: GENETIC
Intervention: cytogenetic analysis

Intervention type: GENETIC
Intervention: fluorescence in situ hybridization

Intervention type: GENETIC
Intervention: gene rearrangement analysis
Study: NCT05702957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole 2.5mg-7.5mg
Description: Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg-150mg
Description: Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
Study: NCT00346034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 to 600mg/day
Study: NCT02268773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid high dose
Study: NCT03416153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
Study: NCT00636922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001(Everolimus)
Description: In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
Study: NCT00941681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: 50 mg MR CK-1827452 BID for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: 37.5 mg IR CK-1827452 TID for 10 days
Study: NCT02192463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 25%) Medium Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 30%) Slow Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 25%) Medium Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 40%) Slow Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (ECR 20%) Fast Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 20%) Medium Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 30%) Slow Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 40%) Slow Release
Study: NCT00941681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: 100 mg MR CK-1827452 BID for 10 days
Study: NCT00464308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Study: NCT02192463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (ECR 20%) Fast Release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine immediate release (IR) 200 mg
Study: NCT02114502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: 30 mL oral rinse four times a day from Day -9 until discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 15 g four times a day, swished, gargled and spit on Day -9 until discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100 mg by vein or mouth three times a day from Day -1.
Study: NCT02192463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine immediate release (IR) 200 mg
Study: NCT00124189

Intervention type: DRUG
Group type: OTHER
Intervention: GRN163L
Description: Weekly intravenous infusion
Study: NCT00450879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03159390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phenylacetate salt of ornithine
Study: NCT01357499

Intervention type: DEVICE
Intervention: blood pressure cuff
Description: A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.

Intervention type: DEVICE
Intervention: blood pressure cuff + electric muscle stimulator
Description: A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
Study: NCT00716599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: training in use of rapid diagnostic tests (RDTs) for malaria
Description: training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers